![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » New Congress to Tackle Drug Pricing Legislation
New Congress to Tackle Drug Pricing Legislation
January 9, 2019
Democratic legislators, including some possible 2020 presidential contenders, are planning to highlight the hot-button issue of drug pricing in the 116th Congress — although the first order of business will be ending the federal government shutdown.
Several Democratic legislators who introduced drug-pricing bills in the last session are expected to reintroduce them as they announce their candidacies for president in the coming months.
In late November, Sen. Bernie Sanders (I-Vt.) — who caucuses with the Democrats — announced the Prescription Drug Price Relief Act, which would require HHS to impose a price ceiling on branded drugs of no more than their median price in Canada, France, Germany, Japan and the United Kingdom. Rep. Ro Khanna (D-Calif.) will introduce an equivalent bill in the House.
Upcoming Events
-
21Oct